Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2021			114,991,000
Beginning balance at Dec. 31, 2021	$ 121,599		$ 11	$ 323,666	$ 0	$ (202,078)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	7,557			7,557
Proceeds from option exercises (shares)			723,000
Proceeds from option exercises	131		$ 1	130
Net (loss) income	44,894					44,894
Foreign currency translation	0
Ending balance (in shares) at Mar. 31, 2022			115,714,000
Ending balance at Mar. 31, 2022	174,181		$ 12	331,353	0	(157,184)
Beginning balance (in shares) at Dec. 31, 2021			114,991,000
Beginning balance at Dec. 31, 2021	$ 121,599		$ 11	323,666	0	(202,078)
Ending balance (in shares) at Dec. 31, 2022	116,432,029		116,432,000
Ending balance at Dec. 31, 2022	$ 97,386	$ (33)	$ 12	350,247	193	(253,066)	$ (33)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2016-13 [Member]
Stock-based compensation	$ 5,286			5,286
Proceeds from option exercises (shares)	30,000		30,000
Proceeds from option exercises	$ 12			12
Proceeds from issuance of stock under the employee stock purchase plan (in shares)			267,401
Proceeds from issuance of stock under the employee stock purchase plan	75			75
Net (loss) income	(24,628)					(24,628)
Foreign currency translation	$ 13				13
Ending balance (in shares) at Mar. 31, 2023	116,729,430		116,729,000
Ending balance at Mar. 31, 2023	$ 78,111		$ 12	$ 355,620	$ 206	$ (277,727)